• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IVS期神经母细胞瘤:45例临床、组织学及生物学分析

Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases.

作者信息

Hachitanda Y, Hata J

机构信息

Division of Pathology, Clinical Laboratory, National Children's Hospital, Tokyo, Japan.

出版信息

Hum Pathol. 1996 Nov;27(11):1135-8. doi: 10.1016/s0046-8177(96)90304-4.

DOI:10.1016/s0046-8177(96)90304-4
PMID:8912820
Abstract

This study reports clinicopathologic and biological analysis of 45 stage IVS neuroblastomas (IVS-NBs). All IVS-NB cases had small or undetectable primary tumors associated with disease involving the liver, skin, or bone marrow. Their ages at diagnosis ranged from 1 day to 12 months, with a median age of 4 months. The primary sites were adrenal in 34 cases, retroperitoneum in two, mediastinum in one, and unknown in eight; the liver was involved in 24 of 31 cases, the bone marrow in 11 of 27, and the skin in 4 of 29. According to the histopathological evaluation (Shimada classification), 43 IVS-NB tumors had a favorable histology, and 2 cases showed an unfavorable histology. Three patients died of progressive disease and six of indirect tumor death. Among these three deceased cases with tumor progression, two cases showed unfavorable histology, and one case had amplified N-myc (20 copies). These data suggest that most IVS-NB can be described as a tumor presenting characteristic dissemination pattern in the younger age group, having a favorable histology and showing an excellent outcome of the patients. However, poor prognosis group in stage IVS does exist, and this group could be detected histopathologically and biologically.

摘要

本研究报告了45例IV-S期神经母细胞瘤(IVS-NBs)的临床病理及生物学分析。所有IVS-NB病例均有小的或无法检测到的原发肿瘤,伴有肝脏、皮肤或骨髓受累。其诊断时年龄范围为1天至12个月,中位年龄为4个月。原发部位:肾上腺34例,腹膜后2例,纵隔1例,8例不明;31例中有24例肝脏受累,27例中有11例骨髓受累,29例中有4例皮肤受累。根据组织病理学评估(岛田分类),43例IVS-NB肿瘤组织学良好,2例组织学不良。3例患者死于疾病进展,6例死于间接肿瘤死亡。在这3例肿瘤进展死亡病例中,2例组织学不良,1例N-myc扩增(20拷贝)。这些数据表明,大多数IVS-NB可描述为在较年轻年龄组中呈现特征性播散模式的肿瘤,组织学良好,患者预后极佳。然而,IV-S期确实存在预后不良组,该组可通过组织病理学和生物学方法检测出来。

相似文献

1
Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases.IVS期神经母细胞瘤:45例临床、组织学及生物学分析
Hum Pathol. 1996 Nov;27(11):1135-8. doi: 10.1016/s0046-8177(96)90304-4.
2
Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator.N - myc癌基因在Ⅱ期和ⅣS期神经母细胞瘤中的扩增可能是一个预后指标。
J Pediatr Surg. 1987 May;22(5):415-8. doi: 10.1016/s0022-3468(87)80260-9.
3
Features and outcome of neuroblastoma detected before birth.出生前检测到的神经母细胞瘤的特征及预后
J Pediatr Surg. 2000 Jan;35(1):88-91. doi: 10.1016/s0022-3468(00)80020-2.
4
Inverse expression of MYCN and mdr-1 in human neuroblastoma.MYCN与mdr-1在人类神经母细胞瘤中的反向表达。
Prog Clin Biol Res. 1991;366:11-9.
5
Prognostic value of N-myc oncogene amplification and S-100 protein positivity in children with neuroblastic tumors.N-myc原癌基因扩增和S-100蛋白阳性在神经母细胞瘤患儿中的预后价值。
Acta Pathol Jpn. 1992 Sep;42(9):639-44. doi: 10.1111/j.1440-1827.1992.tb03044.x.
6
Competitive polymerase chain reaction for the determination of N-myc amplification in neuroblastoma: report of clinical cases.用于测定神经母细胞瘤中N-myc扩增的竞争性聚合酶链反应:临床病例报告
Eur J Pediatr Surg. 1999 Jun;9(3):138-41. doi: 10.1055/s-2008-1072229.
7
N-myc amplification in neuroblastomas: histopathological, DNA ploidy, and clinical variables.神经母细胞瘤中的N-myc扩增:组织病理学、DNA倍性及临床变量
J Clin Pathol. 1989 Nov;42(11):1148-52. doi: 10.1136/jcp.42.11.1148.
8
Stage IVS neuroblastoma.IVS期神经母细胞瘤。
J Pediatr Surg. 1978 Apr;13(2):167-72. doi: 10.1016/s0022-3468(78)80013-x.
9
Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.神经母细胞瘤的大规模筛查:何去何从?来自日本九州地区儿科肿瘤学研究组的9年经验。
J Pediatr Surg. 1996 Apr;31(4):555-8. doi: 10.1016/s0022-3468(96)90495-9.
10
Immunohistochemical analysis of N-myc protein expression in neuroblastoma: correlation with prognosis of patients.神经母细胞瘤中N-myc蛋白表达的免疫组织化学分析:与患者预后的相关性
J Pediatr Surg. 1991 Jul;26(7):838-43. doi: 10.1016/0022-3468(91)90151-i.

引用本文的文献

1
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.定义化疗干预 4S 期神经母细胞瘤婴儿风险因素:来自儿童肿瘤学组研究 ANBL0531 的报告。
J Clin Oncol. 2019 Jan 10;37(2):115-124. doi: 10.1200/JCO.18.00419. Epub 2018 Nov 16.
2
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.诊断为出生至 18 个月的转移性神经母细胞瘤患者中 4S 期转移模式和肿瘤生物学的预后价值。
J Clin Oncol. 2011 Nov 20;29(33):4358-64. doi: 10.1200/JCO.2011.35.9570. Epub 2011 Oct 3.
3
Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
国际神经母细胞瘤病理分类在神经母细胞瘤(少雪旺细胞基质型)中的预后价值及与其他预后因素的比较:一项来自西班牙神经母细胞瘤登记处的182例病例研究
Virchows Arch. 2006 Oct;449(4):410-20. doi: 10.1007/s00428-006-0253-y. Epub 2006 Aug 29.